CT-388
ZYNERGY
Roche · Phase 2 · Not yet recruiting · Enrollment 486
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Arm 1: Petrelintide + Enicepatide Dosing Regimen 1 | n/r | n/r | n/r | n/r |
| Arm 2: Petrelintide + Enicepatide Dosing Regimen 2 | n/r | n/r | n/r | n/r |
| Arm 3: Petrelintide + Enicepatide Dosing Regimen 3 | n/r | n/r | n/r | n/r |
| Arm 4: Petrelintide-matching Placebo + Enicepatide | n/r | n/r | n/r | n/r |
| Arm 5: Petrelintide + Enicepatide-matching Placebo | n/r | n/r | n/r | n/r |
| Arm 6: Petrelintide-matching Placebo + Enicepatide-matching Placebo | n/r | n/r | n/r | n/r |
Not shown
- Arm 1: Petrelintide + Enicepatide Dosing Regimen 1: endpoint not reported
- Arm 2: Petrelintide + Enicepatide Dosing Regimen 2: endpoint not reported
- Arm 3: Petrelintide + Enicepatide Dosing Regimen 3: endpoint not reported
- Arm 4: Petrelintide-matching Placebo + Enicepatide: endpoint not reported
- Arm 5: Petrelintide + Enicepatide-matching Placebo: endpoint not reported
- Arm 6: Petrelintide-matching Placebo + Enicepatide-matching Placebo: endpoint not reported